Evidence map›Paper›PMID 36854856›Full record

ArticlePurinergic signalling2023

P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways.

Xue Bai, Qianqian Li, Xiaoxiang Peng, Xinyu Li, Cuicui Qiao, Yiqing Tang, Ronglan Zhao

Open access · greenAbstract read
In one paragraph

Article in Purinergic signalling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. P2X7 Variants in Pathophysiology.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xue Bai *School of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Qianqian Li *School of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Xiaoxiang Peng *School of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Xinyu LiSchool of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Cuicui QiaoSchool of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Yiqing TangSchool of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Ronglan ZhaoSchool of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China. ronglanzhao@wfmc.edu.cn.ORCID 0000-0002-4302-2563
Weifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been demonstrated that the ATP-gated ion channel P2X7 receptor is involved in tumor progression and plays an important role in regulating tumor cell growth, invasion, migration and angiogenesis. However, P2X7 receptors have been relatively poorly studied in non-small cell lung cancer (NSCLC) cells. Therefore, the aim of this study was to investigate the effects of P2X7 receptor on A549 cells (NSCLC cell line) migration and invasion and to reveal the molecular mechanisms mediated by it. We detected the expression and function of P2X7 receptor in A549 cells. The effects and mechanisms of P2X7 receptor on A549 cells migration, invasion, and epithelial-mesenchymal transition were detected in vitro and in vivo. The results showed P2X7 receptor expressed by A549 cells had ion channel and macropore formation function. In addition, activation of P2X7 receptor by adenosine triphosphate (ATP) or 2'(3')-O-(4-Benzoylbenzoyl)-adenosine-5'-triphosphate (BzATP) promoted Epithelial-mesenchymal transition (EMT), migration and invasion of A549 cells, which was attenuated by treatment of cells with P2X7 receptor antagonist A438079 and Oxidized ATP. Furthermore, activation of P2X7 receptor increased phosphorylated protein kinase B (p-Akt) levels, and the phosphatidylinositol-tris-phosphate kinase 3 (PI3K)/protein kinase B (Akt) inhibitor LY294002 blocked migration and invasion of A549 cells induced by ATP or BzATP. At the same time, in vivo results showed that P2X7 receptor could also promote EMT and PI3K/Akt expression in transplanted tumors. Our study indicated that P2X7 receptor promotes A549 cells migration and invasion through the PI3K/Akt signaling pathway, suggesting that P2X7 receptor may be a potential therapeutic target for NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsA549 CellsAdenosine TriphosphateCell Line, TumorCell MovementCell ProliferationHumansPhosphatesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, Purinergic P2X7Adenosine TriphosphateP2RX7 protein, humanPhosphatesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, Purinergic P2X7InvasionMigrationNon-small cell lung cancerP2X7 receptorPI3K/Akt signaling pathway

Identifiers

PMID36854856
PMCPMC10754800
OpenAlexW4322618465

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.